Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose intravenous ketamine with haloperidol in reducing delirium and agitation
IRCT20230522058252N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine and haloperidol in delirium and agitation, sponsored by Tehran University of Medical Sciences. Started Mar 2021; status: completed.
02
Drugs
ketaminehaloperidol
03
Conditions
deliriumagitation
Beyond the preview
Go deeper on IRCT20230522058252N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230522058252N1.